Cardiovascular disease is a major cause of morbidity and mortality, especially in developed countries. Most academic research efforts in cardiovascular disease management focus on pharmacological interventions, or are concerned with discovering new disease markers for diagnosis and monitoring. Nonpharmacological interventions with therapeutic devices, conversely, are driven largely by novel materials and device design. Examples of such devices include coronary stents, heart valves, ventricular assist devices, and occluders for septal defects. Until recently, development of such devices remained largely with medical device companies. We trace the materials evolution story in two of these devices (stents and occluders), while also highlighting academic contributions, including our own, to the evolution story. Specifically, it addresses not only our successes, but also the challenges facing the translatability of concepts generated via academic research. invasive deployment is of substantial benefit to the patients and for the healthcare system as a whole. This is significant since management of cardiovascular disease is the primary healthcare cost for the developed world. Pharmacological intervention in post-Myocardial Infarction (post-MI) patients deals predominantly with blood-pressure management and anticlotting medication that ironically is necessitated by the presence of the blood-contacting device (stent, in this case); the search for the elusive "plaque-buster" continues but seems to have lost momentum in recent times. Thus, in cardiology, implanted devices dominate in disease management, and in this paper, we review advances in biomaterials-based design of implanted devices, more specifically stents and occluders, including highlighting our own contributions to design and performance enhancements. The underlying theme of our review is translatability of concepts, preferably as demonstrated in the clinic or in well-accepted animal models.
| I N T R O D U C T I O N
Advances in nonpharmacological management of cardiovascular disease are largely driven by clever use of established biomaterials, or the development of new ones. When we talk of advances in management, we refer to patient benefits such as reducing the complexity of the procedures used, shorter healing periods and arresting the progression of disease. The complexities and morbidities associated with open heart surgery are well-known. Any advance that results in minimally invasive deployment is of substantial benefit to the patients and for the healthcare system as a whole. This is significant since management of cardiovascular disease is the primary healthcare cost for the developed world. Pharmacological intervention in post-Myocardial Infarction (post-MI) patients deals predominantly with blood-pressure management and anticlotting medication that ironically is necessitated by the presence of the blood-contacting device (stent, in this case); the search for the elusive "plaque-buster" continues but seems to have lost momentum in recent times. Thus, in cardiology, implanted devices dominate in disease management, and in this paper, we review advances in biomaterials-based design of implanted devices, more specifically stents and occluders, including highlighting our own contributions to design and performance enhancements. The underlying theme of our review is translatability of concepts, preferably as demonstrated in the clinic or in well-accepted animal models.
Both the design and the materials of implanted devices such as heart valves, coronary stents, and occluders have undergone dramatic changes driving the transition from surgical implantation to percutaneous deployment. This is a tremendous leap in the use of device technology, and confers obvious benefits to the patient: the procedure is minimally invasive, it is relatively painless and can be done as an outpatient procedure; and the subsequent healing period is drastically shortened. Both patient and healthcare system costs are thus dramatically reduced.
The revolution in management of MI started with the advent of balloon angioplasty in the late 1970s; this was made possible via the invention of the balloon catheter, by Dr. Gruntzig. 1,2 This catheter incorporated a remarkable segment (the "balloon") that could be expanded in situ at the stenosed section of the coronary artery by hydrostatic pressure, while guided by X-ray fluoroscopy to the site of blockage. Most importantly, the catheter was inserted through an artery in the leg or arm, and contained radio-opaque segments that made it visible in X-ray. Although balloon angioplasty replaced bypass surgery as the first option for patients with a single blocked artery, the procedure still led to re-blockage of the stenosed artery, resulting in reintervention rates of 40-50% that were unacceptable.
As one of the reasons for the restenosis was vessel recoil, the insertion of a slotted stainless-steel tube (stent) concurrent or subsequent to balloon angioplasty was approved in 1993. This concept of a coronary stent, envisaged by a cardiologist named Julio Palmas was so revolutionary that he could not find anyone willing to fund it, until a Texas restauranteur named Phil Romano put up some initial funding of $250,000. Following successful human trials this stent known as the Palmas stent was approved in 1994. 3 From such humble beginnings, the bare metal stent has undergone significant design and material changes to the present-day Co-Cr stent, which has a strut thickness of about 90 microns. 4 Ironically, while the bare metal stent was being deployed more and more widely, it was noted that restenosis rates were still around 20-30%; this restenosis was triggered largely by uninhibited growth of smooth muscle cells ironically by the use of drugs such as paclitaxel and sirolimus that did not discriminate between proliferating SMCs and ECs. Although such thrombotic events were rare, they were fatal. This led a few cardiologists to think about fully resorbable stents, as evidence mounted that stents were really needed only for about 6-9 months. 6, 7 After this period, stents were not only redundant but also a liability, as their presence necessitated the use of anticlotting drugs and their presence was counter-indicated for certain procedures such as MRI imaging.
The pace of research progress in this area is astounding, and largely led by medical-device industry R&D up to the point where the first notion of fully resorbable stents was mooted. The fully absorbable stent concept arose in a medical school, and was developed by Japanese researchers, Dr. Igaki and Tamai, and eventually licensed to Kyoto Medical Planning.
This nondrug eluting stent was first reported to have undergone human trials in 2000. 8 The Igaki-Tamai stent used a hydrolytically degradable polymer called Poly (L-lactide) which had been used as a suture material in surgery, and is known to degrade over a period of 12-24 months.
Our involvement in the fully degradable stent research started in 2003, with a grant from Singapore's Ministry of Education. Concurrently, we also worked on a metal stent coated with a biodegradable polymer that delivered two drugs, an antiproliferative (sirolimus) and antithrombotic (triflusal). 9 We describe our efforts to translate these concepts to the clinic in Sections 2.2.1 and 3.1.1. All abbreviations used are listed in Table 5 .
| D U A L-D RU G -E LU T IN G ST E N T S 2.1 | Background on drug types
The first generation of DES includes the sirolimus-eluting stent (Cypher®) and the paclitaxel-eluting stent (Taxus®), with both demonstrating impressive reductions in restenosis from 50 to 20/30% compared with bare metal stents (BMS). However, due to incomplete healing, the incidence of late stent thrombosis (LST) marred their longterm use, especially after discontinuation of dual antiplatelet therapy. 5 Paclitaxel is a lipophilic molecule with potent antiproliferative and antimigratory activities. The drug is a microtubule-stabilizing agent, which enhances formation of microtubular polymerized structures and thus, decreases the concentration of tubulin required for new microtubule formation. Paclitaxel affects primarily the M phase of the cell cycle inhibiting growth factor-induced DNA synthesis and cell proliferation, and leads to apoptosis or cell death. Concerns regarding cardiotoxicity of paclitaxel has been one of the reasons for its slow eclipse.
Currently, it appears that the limus-family of eluting stents dominates the market, as shown in Table 1 ; they stop the cell cycle at the G0/G1 phase inhibiting both cell (mainly smooth muscle cells) proliferation and migration, so the mechanism of action is cytostatic rather than cytotoxic. Tacrolimus and pimecrolimus are not analogs of the archetypal rapamycin; after they bind intracellularly to FKBP12, the complex in turn binds to and blocks calcineurin, and in this way inhibits the T-cell transduction pathways and the synthesis of pro-inflammatory cytokines. 12 In vitro cell work indicates that tacrolimus allows earlier endothelial regeneration than sirolimus; however, inhibitory activity on human vascular SMCs with tacrolimus is much less than sirolimus. 13 In this context, both everolimus-eluting stents (EES) and biolimus-eluting stents (BES) are the front-runners, and likely to be approved (or already approved) as noninferior products.
| Drug-eluting stents in research
Long term follow-up studies of DES have shown increased incidence of (sometimes fatal) stent thrombosis probably due to delayed endothelialization by the currently used drugs or delayed hypersensitivity reaction caused by the durable polymer; or by degraded polymer products currently used in DES. [14] [15] [16] An array of slow, moderate and fast release profiles were attained from the addition of poly(ethylene glycol) and its copolymers in formulations for 30 days. 21 Following this, a 4-week pig study was carried out with a total of 32 stents implanted into 16 pigs. 22 The in vivo results demonstrated significantly higher plasma levels of CD-NP in the CES, and greater endothelial coverage of the stent struts compared with a control group (BMS and polymer-coated stent) at poststenting, as shown in Figure 1 .
We believe that ensuring unperturbed endothelium regeneration is crucial to avert further progression of in-stent restenosis and LST.
However, the CES group was not able to show a significantly different outcome in terms on stenosis, when compared to BMS. This led us to believe that 2 lg/day over 28 days dosing of CD-NP used in this study was not sufficient to activate sufficient cGMP locally or systemically to have a significant effect on SMC proliferation. Further detailed studies, incorporating higher doses and frequent sampling, are therefore warranted.
| Dual drug-eluting stents
Drug-eluting stents could include two therapeutic agents, antiproliferative and pro-healing, which would help in further enhancing the antirestenotic performance of currently available DES, and would promote healing performance. The selection of an appropriate therapeutic combination and the regulation of their release kinetics are important for successful performance of a DDES. In our review in 2014, 10 we have surveyed and categorized DDES into three types: antiproliferative with antithrombotic, antiproliferative with re-endothelialization promoter, and dual antiproliferative agents (independent pathways). Currently, although several DDES are in clinical trials, none has been approved for commercial use. We have developed a DDES that elutes sirolimus (an antiproliferative) and triflusal (an antithrombotic) to treat both restenosis and thrombosis. 9 This DDES consists of a cobalt-chromium stent with strut dimensions 0.075 3 0.080 mm (W 3 T), and a twolayered coating including a biodegradable poly (lactic-co-glycolic) acid (PLGA) drug layer and a drug-free top layer to control the drug release.
The cumulative release profile showed an initial burst of about 30% for sirolimus, and subsequent release to 60% by day 14, and more than 70% cumulative sirolimus release after 30 days. In contrast, approximately 60% of burst release and almost complete release in about 5 days was registered for trifusal.
A 24-pig study 23 (expanded stent/artery 5 1. This is an example of a translatable concept that has shown very promising preclinical results in an accepted animal model for restenosis.
However, the generation of the strong efficacy data was reported at a time when the interventional cardiology community was turning away from DES toward BMS, because of the concerns raised regarding latestage thrombosis in DES-stented patients. Hence the work went no further, due to lack of interest from the investment community. Meanwhile, the momentum regarding fully bioabsorbable stents had taken hold, and efforts were re-directed to the more challenging but potentially more rewarding area of resorbable stents.
| F U L LY BI O RE S O R B A B L E S T EN T S 3.1 | Fully bioresorbable stents in the market
It has been recognized for some time, that a fully resorbable stent is a preferred option for unblocking coronary arteries, deployed via percutaneous coronary intervention (PCI). The concept of a temporary multifunctional stent that enables revascularisation of the artery via a mechanical support like a metallic stent; prevention of restenosis by sustained-delivery of an antirestonotic like a DES; and allowing the restoration of normal vasomotion after resorption, has been considered the "holy-grail" of a fourth-generation stenting technology. 24 However, despite the many positive attributes that bioresorbable stents are expected to bring, there has been so far only two companies obtaining regulatory approval for such implants.
The world's first bioresorbable stent that found its way into humans was the implanted Igaki-Tamai stent at the turn of this century. 8 The stent was made with poly-L-lactide (PLLA) and expanded in the artery via a heated delivery balloon. The first-in-human (FIM) study involved a total of 25 such stents implanted in 15 patients. Together with a second trial, clinical results were promising, but usage was not extended to PCI due to the complexity involving the thermal balloon. 25 Although the stent was deployed percutaneously in the study, it needed to be heated to about 708C briefly, in order to overcome the natural recoil of the viscoelastic PLLA on balloon expansion. This problem in deployment got us interested in using shape memory concepts in deploying the sent. 26 The leader in the field of fully absorbable coronary stents is Abbott 29 The radial strength of these constructs was studied and reported. 30 Other studies included biodegradation, drug release from coatings, and the viscoelasticity and shape memory properties of the materials used, as shown in Figure 3 .
Our initial focus was on ureteric stents, where the ureter was also subject to stenosis due to various causes; a fully bioabsorbable stent had to degrade in about 4-6 weeks in this case. 33 Based on this work, The IDEAL BioStent by Xenogenics Corporation (Woonsocket, Rhode Island) is a sirolimus-eluting bioresorbable stent based on a polyanhydride ester mixed with salicylic acid. 25 The stent has both antiproliferative and anti-inflammatory properties attributable to its dual release capability for salicylic acid and sirolimus. An FIM study on an earlier version enrolled 11 patients and results were unsatisfactory due to excessive neointimal growth. 25 The current design is under development and in clinical trials, but not much information has been released thus far. Details of these are summarized in Table 2 .
| O C C L U S I O N D E V I C E S F O R S T R U C T U R A L H E A R T DI S E A S E 4.1 | Review of occlusion devices in the market
Atrial septal defect (ASD) and patent ductus arteriosus (PDA) are two major types of congenital heart diseases. ASD is defined as a persistent communication between the right and left atria. The incidence of ASD is about 1 in 2000 newborns 40 and this accounts for 7-10% of all congenital heart defects in adults. 41 Patients with unrepaired ASD can lead to The polymer has a half-life in vivo of about 6 months: (a) molecular weight loss in vitro and (b) molecular weight loss in vivo complications such as atrial arrhythmias, pulmonary hypertension, and cardiac failure. 42 On the contrary, PDA is an open channel allowing mixing of oxygenated and deoxygenated blood from the aorta to the pulmonary artery. The incidence of PDA is about 1 in 2000 newborns, accounting for 5-10% of all coronary heart diseases. 43 If the PDA is large and left untreated, this condition can cause symptoms such as fatigue, difficult or rapid breathing, failure to grow normally, or eventually heart failure and death.
As ance, 98.5% closure rate with no signature residual shunt (less than 2 mm) is reported at 1-year follow-up. 44 Nonetheless, serious complication of device erosion has been reported, with an estimated worldwide implant rate of 0.2-0.5%. 45 The mechanism is thought to be compliance mismatch between the left atrial disk wire mesh and the atrial wall.
The HSO device assumes a double disk configuration following deployment of a helical nitinol wire frame covered with expanded polytetrafluoroethylene (ePTFE). A maneuver is performed to lock the two disks together prior to the release of the delivery catheter. Five device sizes, ranging from 15 to 35 mm, are available and designed to close defects that are 18 mm in diameter. Subsequently, the HSO device has been upgraded to GORE® Cardioform Septal Occluder (GSO), which was granted CE mark in June 2011 for the treatment of patent foramen ovale (PFO) and ASD. The GSO is modified with a flexible, retrievable, double disc configuration with a petal design made of platinum-filled nitinol frame covered with a thin hydrophilic surface-treated ePTFE membrane to facilitate rapid endothelialization. These features have improved the device apposition ability and tissue response while keeping its atraumatic design, low septal profile with minimal septal distortion, and long-term biocompatibility. 46 The success rate for deployment is high (89%) with an acceptable small residual shunt is reported with GSO. 41 Having softer disk with less frictional forces, the efficacy was similar to the ASO with a low risk of a major adverse event, such as fracture or embolization and no erosion has been reported yet, even in deficient rim complex ASDs. 48 The occlusion devices for ASD in the market are summarized in Table 3 . pletely occlude the ductus. 49 Besides Ginaturco coil, the Nit-Occlud PDA system is also utilized for closure of small to medium-sized PDAs.
It is similar in appearance with Ginaturco coil but has many more loops of varying diameters that stack to form a cone. Only the anterior loops of this device are positioned in the pulmonary artery while the remainder loops are generally placed in the aortic ampulla of the ductus.
For the closure of large PDAs, Amplatzer duct occluder (ADO) is the preferred choice. ADO is made of nitinol wire mesh that is configured into a cylindrical plug shape with a retention skirt to better anchor the device within the ductus and reduce embolization. Polyester fabric is sewn into the occluder to induce the thrombosis that closes the communication. In term of safety and efficacy, the successful deployment rate of ADO is 99.2% in a total of 390/393 patients with overall a 5.8% adverse event. Complete closure of the ductus was 98.4% at the 6-month interval and 98.6% at the 12-month interval. 50 A second generation of ADO, Amplatzer Duct Occluder II (ADO II), was granted FDA approval on 2013.
ADO II consists of fabric-free symmetrical multilayered nitinol mesh and dual articulating discs providing high conformability to treat the nonconical ducts, small infants with larger duct diameters while achieving compete closure from an aortic or pulmonary artery deployment approach. In a series of clinical trials, it demonstrates the safety and efficacy of the ADO II to occlude PDA with diameter that is 2 mm with successful deployment rate of 93.3% in a total of 56/60 pediatric patients. [51] [52] [53] The occlusion devices for PDA in the market are also summarized in Table 3 .
| Occlusion devices in preclinical research
Device closure of appropriately indicated ASD and PDA is standard of care in most countries. All current commercial devices use a metallic frame and occlusive patch material. Metallic frameworks are recognized as the major cause of serious complications such as erosion, perforation, metal fractures, nickel ions elution and allergy, reported as late as 10 years following implantation. 54 Therefore, fully bioresorbable occluders are desirable: such an occluder not only closes the defect, but also act as a temporary scaffold for tissue regrowth and eventually "goes away" leaving host tissue behind with minimal long-term consequences. The occlusion devices in research are summarized in Table 4 .
A partially degradable ASD closure device, Biostar, was first devel- the devices were in stable position with no shunt and were well endothelialzied after the 1-month follow-up. 54 The Chinese lantern occluder consists of soft portion ("head," "waist," and "tail" films) and structural skeleton (lock, and head tubes, and wires) with unique pull-fold mechanism to achieve folding and sealing. On retraction of the loop wire, the head films and tail films will fold into the working structure (Figure 7b) with the waist film length being adjustable corresponding to the septum thickness. In term of material, blend of PLC, PCL, and BaSO4 were utilized for the occluder fabrication. Preclinical study was also conducted in swine model, with satisfactory X-ray visibility. At the 1 month follow-up, there was no shunt from right atrium to the left atrium and complete endothelialization of the device. 60 Also, our group has developed a fully bioresorbable PDA occluder.
Build on the double umbrella concept, our PDA occluder consists of three parts: an anchoring arm, a stem and an umbrella with spokes with pull-fold mechanism in order to be repositionable and retrievable during the deployment (Figure 7c ). The umbrella serves to cover the PDA and needs to recover as fast as possible postdeployment to ensure a fast delivery procedure. Therefore, PLC is used as the umbrella material for it is elastomeric and possesses good recovery property. The spokes on the umbrella serve as a structural support during deployment as blood pressure turbulence is experienced in the aortic side of the heart. Since both 59 recoverability and mechanical strength are both required for the spokes, the PCL/PLC blend is used to give an optimum mix of recoverability and strength. Similarly, PCL/PLC blend is also chosen as the material for the anchoring arm, which serves to anchor and immobilize the device within the conduit of the PDA. During the sheathing process, the anchoring arm is folded inwards toward the stem to enable the device collapse into the deployment sheath. Once deployed, the four arms should open up and recover the original structure and then rest/grip onto the inner side of the PDA lumen, thus ensuring that the device stays in place. Lastly, the stem serves as the backbone of the PDA occlusion device, connecting both the anchoring arm and the umbrella. This part of the device has to withstand high stress: therefore, the blend of PCL and BaSO4 is chosen as the material for it has the highest modulus among the blends. Furthermore, with the addition of BaSO4 into the stem and anchoring arm parts, the PDA occluder is radiopaque so that it can be easily monitored by fluoroscopy and accurately placed. 61 Our in vivo feasibility study demonstrated that the PDA device was able to recover within 2-3 min in vivo for immediate PDA closure and tissue overgrowth on the device at 1-month follow-up result, indicating the possibility of usage in human being. 62 
| C ONC LUD I NG RE MARKS
It is now recognized that opening and closing of selected body vessels or defects is preferably done with a temporary scaffold rather than a biostable one, whose permanence may lead to serious side effects. Our translational efforts in two such fully bioabsorbable cardiovascular implants were seed-funded by academic grants; we believe these constitute some of the very rare examples of academically driven translation in such implanted devices. Although scale-up and manufacture of the implants required substantial follow-on funding, these examples of stents and occluders demonstrate the possibility of pushing inventions in academia to the clinic, slower though the overall process may be in comparison to concerted industrial efforts. The successful translation of our coronary stent was possible because there was significant follow-on funding available for it, as the coronary stent space is competitive because of its large market size. In contrast, our work on fully absorbable stents for blocked ureteric and trachea, both of which are unmet medical needs at present, remain untranslated because they both address small markets (<$50 M each worldwide). Medical device companies do not pursue such options because the return on investment is not as high as, for example, with coronary stents or ventricular assist devices. The story is similar with occluders: occluder companies are few and far apart, and most if not all are too small to afford R&D in second and third-generation devices. While our own occluder prototype development was funded largely by academic grants, follow-on funding was (and remains) difficult to obtain for translating these small-market devices to the clinic. This is a pity. In the coming years, it is hoped that such efforts, that address genuine medical needs, can be funded by nonprofit organizations or even by academic institutions. Such funding need not be in conflict with University ethics; on the contrary, it may fit in very well with the stated (and unstated) goal of academic institutions to serve their communities in ways beyond education.
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